14862-80-7

Usage

Explanation

The molecular formula represents the number of atoms of each element present in a molecule of the compound.

Explanation

It is a compound derived from a ketone, which is a carbonyl-containing functional group.

Explanation

The compound has a piperidine ring (a saturated heterocyclic amine) and a phenyl ring (a six-carbon aromatic ring) in its structure.
4. Pharmaceutical Intermediate

Explanation

It is used in the synthesis of various medications, playing a crucial role in the production of pharmaceuticals.

Explanation

The compound is used in the development of medications that treat high blood pressure (antihypertensive) and allergies (antihistamine).

Explanation

The compound can interact with specific receptors, which may contribute to its pharmacological effects.

Explanation

It may influence the activity of neurotransmitters, which are chemicals that transmit signals in the nervous system.

Explanation

Research is being conducted to explore the compound's potential as a therapeutic agent for treating different health issues.

Explanation

The solubility of the compound in various solvents is not provided in the given information.

Explanation

Information about the compound's stability under different conditions is not available in the provided material.

Chemical Class

Ketone derivative

Structural Components

Contains a piperidine and phenyl structure

Applications

Antihypertensive and antihistamine drugs

Receptor Binding

Ability to bind to specific receptors in the body

Neurotransmitter Function

Potential to affect neurotransmitter function

Therapeutic Potential

Studied for treatment of various medical conditions

Solubility

Not mentioned in the material

Stability

Not mentioned in the material

Upstream product

• 71-43-2 benzene 
• 57988-60-0 4-hydroxy-4-(4-methylphenyl)-piperidine 
• 939-52-6 4-chloro-1-phenylbutan-1-one 
• 1260882-14-1 tert-butyl 4-hydroxy-4-(p-tolyl)piperidine-1-carboxylate 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 220525-47-3 4-Brom-4-phenyl-piperidin 
• 40807-61-2 4-hydroxy-4-phenylpiperidin 

Relevant academic research and scientific papers

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Phenylbutanol derivatives

Butyrophenone derivatives having excellent psychotropic activity and represented by the formula, SPC1 Wherein A represents a single or double bond linkage; R1 represents a hydrogen atom or a C1 - C4 alkyl group; R2, which is present only in case A represents a single bond linkage, represents a hydrogen atom, or a hydroxyl, C1 - C4 alkyl, or C1 - C4 alkoxy group; R3 represents a hydrogen atom, or a piperidino, pyrrolidino, morpholino, furyl, thienyl, C1 - C4 alkylamino, benzylamino, unsubstituted or halogen-substituted phenyl group, etc.; and X represents a hydrogen or halogen atom, or a C1 - C4 alkyl, C1 - C4 alkoxy, or trifluoromethyl group, can be prepared by reducing a benzoylpropionamide derivative of the formula, SPC2 Wherein A, R1, R2, R3 and X have the same meanings as defined above, to a phenylbutanol derivative of the formula, SPC3